ARWR vs IDYA

Arrowhead Pharmaceuticals continues to demonstrate strong 10x growth potential within 3-5 years, underpinned by its advanced TRiM RNAi platform and a robust pipeline targeting high-value indications. The recently reported Q1 2026 financials (fiscal quarter ended Dec 31, 2025), showing a significant revenue beat of $264.03M and a positive net margin of 18.54%, validate the commercial potential and ...

IDEAYA Biosciences maintains a strong score, reflecting its pioneering role in synthetic lethality oncology, a field with immense unmet needs and significant market potential. The robust GSK partnership continues to validate its platform, providing critical non-dilutive funding and extending cash runway, which is vital for an early-stage biotech. Clinical programs like darovasertib (uveal melanoma...